Drug intelligence / Profile preview

22ND06

Development stage: Preclinical
Lead developer: HK inno.N Corporation
Modality: Small Molecules

Overview

22ND06 is a small molecule drug candidate currently in the discovery stage of development by HK inno.N (formerly CJ HealthCare). It is being investigated for the treatment of diabetes. As of early 2026, the specific biological target and mechanism of action have not been publicly disclosed. The drug is part of HK inno.N's research and development pipeline focusing on metabolic disorders and represents an early-stage effort to expand their therapeutic portfolio beyond their lead gastrointestinal products.

Beyond the preview

Go deeper on 22ND06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 22ND06.

Explore the full profile